BR0108847A - Sequência de aminoácidos facilitando a penetração de uma substância de interesse no interior de células e/ ou de núcleos celulares - Google Patents
Sequência de aminoácidos facilitando a penetração de uma substância de interesse no interior de células e/ ou de núcleos celularesInfo
- Publication number
- BR0108847A BR0108847A BR0108847-5A BR0108847A BR0108847A BR 0108847 A BR0108847 A BR 0108847A BR 0108847 A BR0108847 A BR 0108847A BR 0108847 A BR0108847 A BR 0108847A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- vector
- interest
- substance
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
"SEQuêNCIA DE AMINOáCIDOS FACILITANDO A PENETRAçãO DE UMA SUBSTâNCIA DE INTERESSE NO INTERIOR DE CéLULAS E/ OU DE NúCLEOS CELULARES". A presente invenção tem por objetivo uma seq³ência de aminoácidos apresentando a capacidade de facilitar a penetração de uma substância de interesse no interior de células e/ ou de núcleos celulares, caracterizada por ser capaz de reagir in vivo com os aminoglicanos. Eventualmente, a dita seq³ência é extraída de uma proteína de origem humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002621A FR2805821B1 (fr) | 2000-03-01 | 2000-03-01 | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires |
PCT/FR2001/000613 WO2001064738A2 (fr) | 2000-03-01 | 2001-03-01 | Sequences d"acides amines derivees des proteines humaines reagissant avec l"heparine facilitant le transfert de substances d"interet a l"interieur des cellules et/ou des noyaux cellulaires |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108847A true BR0108847A (pt) | 2003-02-18 |
Family
ID=8847589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108847-5A BR0108847A (pt) | 2000-03-01 | 2001-03-01 | Sequência de aminoácidos facilitando a penetração de uma substância de interesse no interior de células e/ ou de núcleos celulares |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1259541B1 (pt) |
JP (1) | JP4912556B2 (pt) |
AT (2) | ATE372346T1 (pt) |
AU (1) | AU780785B2 (pt) |
BR (1) | BR0108847A (pt) |
CA (1) | CA2401613A1 (pt) |
DE (2) | DE60137801D1 (pt) |
DK (1) | DK1259541T3 (pt) |
ES (1) | ES2292567T3 (pt) |
FR (1) | FR2805821B1 (pt) |
IL (3) | IL151399A0 (pt) |
PT (1) | PT1259541E (pt) |
WO (1) | WO2001064738A2 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003595B2 (en) | 2000-03-01 | 2011-08-23 | Cellectis | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
JP4387669B2 (ja) | 2000-10-13 | 2009-12-16 | ザイジェン エス.アー. | 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達 |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
FR2841902A1 (fr) * | 2002-07-08 | 2004-01-09 | Diatos | Peptides lineaires cationiques ayant des proprietes antibacteriennes et/ou antifongiques |
EP1512696A1 (en) * | 2003-08-14 | 2005-03-09 | Diatos | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
FR2858772A1 (fr) * | 2003-08-14 | 2005-02-18 | Diatos | Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe |
WO2005018650A2 (fr) * | 2003-08-14 | 2005-03-03 | Diatos | Composition anti-bacterienne plus particulierement contre les bacteries gram negatif comprenent un peptide et un agent anti-bacterien avantageusement hydrophobe |
WO2007054814A1 (en) | 2005-11-14 | 2007-05-18 | Centre National De La Recherche Scientifique - Cnrs | Inhibitors of parp activity and uses thereof |
EP1797901A1 (en) | 2005-12-16 | 2007-06-20 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
EP1818395A1 (en) * | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
AU2007232206B2 (en) * | 2006-03-30 | 2013-04-04 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
EP2172209A1 (en) | 2008-10-03 | 2010-04-07 | Universite Pierre Et Marie Curie | Treatment of mood and anxiety disorders |
EP2539445B1 (en) | 2010-02-26 | 2018-03-21 | Cellectis | Use of endonucleases for inserting transgenes into safe harbor loci |
FR2968662B1 (fr) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
EP2714971A4 (en) * | 2011-05-23 | 2015-01-21 | Phylogica Ltd | METHOD FOR DETERMINING, IDENTIFYING AND INSULATING CELL-PENETRATING PEPTIDES |
JP6517018B2 (ja) * | 2012-02-09 | 2019-05-22 | ヴァー2・ファーマシューティカルズ・アンパルトセルスカブVAR2 Pharmaceuticals ApS | コンドロイチン硫酸グリカンのターゲティング |
GB201322396D0 (en) | 2013-12-18 | 2014-02-05 | Univ Nottingham | Transduction |
CN112457383B (zh) * | 2020-12-16 | 2022-06-17 | 阿南达 | 一种多肽、制备方法及其医药用途 |
AU2022409717A1 (en) | 2021-12-16 | 2024-05-30 | Pags Co., Ltd. | Cell penetrating polypeptides (cpps) and their use in human therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60233099A (ja) * | 1984-05-04 | 1985-11-19 | Asahi Chem Ind Co Ltd | 新規なペプチド |
DK455789D0 (da) * | 1989-09-15 | 1989-09-15 | Symbicom Ab | Polypeptid |
WO1996008274A2 (en) * | 1994-09-13 | 1996-03-21 | Prizm Pharmaceuticals, Inc. | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
FR2736642B1 (fr) | 1995-07-10 | 1997-09-12 | Pasteur Institut | Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques |
US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
FR2766826B1 (fr) * | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
-
2000
- 2000-03-01 FR FR0002621A patent/FR2805821B1/fr not_active Expired - Fee Related
-
2001
- 2001-03-01 DE DE60137801T patent/DE60137801D1/de not_active Expired - Fee Related
- 2001-03-01 DK DK01911821T patent/DK1259541T3/da active
- 2001-03-01 ES ES01911821T patent/ES2292567T3/es not_active Expired - Lifetime
- 2001-03-01 EP EP01911821A patent/EP1259541B1/fr not_active Expired - Lifetime
- 2001-03-01 IL IL15139901A patent/IL151399A0/xx active IP Right Grant
- 2001-03-01 AT AT01911821T patent/ATE372346T1/de active
- 2001-03-01 EP EP04292771A patent/EP1526183B1/fr not_active Expired - Lifetime
- 2001-03-01 AU AU40748/01A patent/AU780785B2/en not_active Ceased
- 2001-03-01 DE DE60130324T patent/DE60130324T2/de not_active Expired - Lifetime
- 2001-03-01 WO PCT/FR2001/000613 patent/WO2001064738A2/fr active Application Filing
- 2001-03-01 BR BR0108847-5A patent/BR0108847A/pt not_active Application Discontinuation
- 2001-03-01 JP JP2001564231A patent/JP4912556B2/ja not_active Expired - Fee Related
- 2001-03-01 PT PT01911821T patent/PT1259541E/pt unknown
- 2001-03-01 CA CA002401613A patent/CA2401613A1/fr not_active Abandoned
- 2001-03-01 AT AT04292771T patent/ATE423849T1/de not_active IP Right Cessation
-
2002
- 2002-08-21 IL IL151399A patent/IL151399A/en not_active IP Right Cessation
-
2008
- 2008-03-31 IL IL190542A patent/IL190542A0/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4912556B2 (ja) | 2012-04-11 |
IL190542A0 (en) | 2008-11-03 |
WO2001064738A3 (fr) | 2002-09-06 |
EP1259541B1 (fr) | 2007-09-05 |
DE60137801D1 (de) | 2009-04-09 |
EP1526183A3 (fr) | 2005-12-07 |
DE60130324T2 (de) | 2008-05-29 |
FR2805821B1 (fr) | 2004-01-16 |
EP1259541A2 (fr) | 2002-11-27 |
DE60130324D1 (de) | 2007-10-18 |
ATE423849T1 (de) | 2009-03-15 |
FR2805821A1 (fr) | 2001-09-07 |
CA2401613A1 (fr) | 2001-09-07 |
DK1259541T3 (da) | 2008-01-07 |
WO2001064738A2 (fr) | 2001-09-07 |
AU4074801A (en) | 2001-09-12 |
JP2003528596A (ja) | 2003-09-30 |
EP1526183B1 (fr) | 2009-02-25 |
ATE372346T1 (de) | 2007-09-15 |
EP1526183A2 (fr) | 2005-04-27 |
ES2292567T3 (es) | 2008-03-16 |
IL151399A (en) | 2008-11-26 |
PT1259541E (pt) | 2007-12-17 |
IL151399A0 (en) | 2003-04-10 |
AU780785B2 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL190542A0 (en) | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei | |
AR006188A1 (es) | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". | |
ATE256186T1 (de) | Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten | |
ES2096750T3 (es) | Vectores retroviricos utiles para la terapia genica. | |
Chattopadhyay et al. | Peptides that anneal to natural collagen in vitro and ex vivo | |
GR3031509T3 (en) | Keratinocyte growth factor (KGF) for its use in method of therapeutic treatment for the human or animal body. | |
IL133253A0 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
ES2181281T3 (es) | Formulaciones liquidas de interferon beta. | |
Deptuła et al. | Development of a peptide derived from platelet-derived growth factor (PDGF-BB) into a potential drug candidate for the treatment of wounds | |
KR20170097830A (ko) | 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
CN106488928B (zh) | 具有抗炎症、骨形成及生发促进活性的肽及其的用途 | |
JP2021073217A (ja) | 胎盤細胞外マトリクスを使用する口腔病変の治療 | |
Mattioli et al. | Osteo-regenerative potential of ovarian granulosa cells: an in vitro and in vivo study | |
WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
PT84089A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
Lian et al. | Effects of induced pluripotent stem cells-derived conditioned medium on the proliferation and anti-apoptosis of human adipose-derived stem cells | |
ATE258442T1 (de) | Matrixprotein zusammensetzungen für pfropfung in nicht mineralisierten geweben | |
Wang et al. | Thermal-induced denaturation of two model proteins: effect of poloxamer 407 on solution stability | |
WO2003092598A3 (en) | Treatment for pompe disease | |
IL145403A0 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients | |
ATE239749T1 (de) | Phosphor-enthaltende dendrimere als transfektionsagente | |
WO2004084800A3 (en) | A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use | |
CN1853609A (zh) | 酸性纤维母细胞生长因子(fgf-1)应用于护肤功效 | |
GHOFAR | DEVELOPMENT OF CONDITIONED MEDIUM DERIVED FROM RAT AMNIOTIC FLUID STEM CELLS SUITABLE FOR RESTORATION OF DIABETIC WOUND | |
UA91488C2 (ru) | Новый класс физиологически активных гликопротеинов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 7/06 (2006.01), A61K 47/42 (2017.01), A61K 47 |
|
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |